Literature DB >> 2016287

Structural determination and immunochemical characterization of the type V group B Streptococcus capsular polysaccharide.

M R Wessels1, J L DiFabio, V J Benedì, D L Kasper, F Michon, J R Brisson, J Jelínková, H J Jennings.   

Abstract

The type V capsular polysaccharide of group B Streptococcus has been isolated and purified, and its repeating unit structure determined. The native type V polysaccharide contains D-glucose, D-galactose, 2-acetamido-2-deoxy-D-glucose, and sialic acid in a molar ratio of 3:2:1:1. Methylation analysis and 1H NMR and 13C NMR analysis of the native type V polysaccharide and of its specifically degraded products permitted the determination of the repeating unit structure of the type V polysaccharide: [formula: see text] The type V polysaccharide has certain structural features in common with other group B streptococcal capsular polysaccharides but is antigenically distinct: no immunologic cross-reactivity was observed between type V and types Ia, Ib, II, III, or IV polysaccharides. Studies of antibody binding to the partially degraded forms of the type V polysaccharide indicated that the native epitope is complex, involving most if not all of the sugar residues of the repeating unit.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2016287

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity.

Authors:  Ravin Seepersaud; Sean B Hanniffy; Peter Mayne; Phil Sizer; Richard Le Page; Jerry M Wells
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

2.  Lectin site interaction with capsular polysaccharide mediates nonimmune phagocytosis of type III group B streptococci.

Authors:  E A Albanyan; M S Edwards
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Structure of the type IX group B Streptococcus capsular polysaccharide and its evolutionary relationship with types V and VII.

Authors:  Francesco Berti; Edmondo Campisi; Chiara Toniolo; Laura Morelli; Stefano Crotti; Roberto Rosini; Maria Rosaria Romano; Vittoria Pinto; Barbara Brogioni; Giulia Torricelli; Robert Janulczyk; Guido Grandi; Immaculada Margarit
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

4.  Group B streptococcal capsular sialic acids interact with siglecs (immunoglobulin-like lectins) on human leukocytes.

Authors:  Aaron F Carlin; Amanda L Lewis; Ajit Varki; Victor Nizet
Journal:  J Bacteriol       Date:  2006-09-22       Impact factor: 3.490

5.  Specificity and prevalence of natural bovine anti-alpha galactosyl (Galalpha1-6Glc or Galalpha1-6Gal) antibodies.

Authors:  Y Ni; R Powell; D D Turner; I Tizard
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

6.  Characterization of CMP-N-acetylneuraminic acid synthetase of group B streptococci.

Authors:  R F Haft; M R Wessels
Journal:  J Bacteriol       Date:  1994-12       Impact factor: 3.490

Review 7.  Biomimetic strategies based on viruses and bacteria for the development of immune evasive biomaterials.

Authors:  Matthew T Novak; James D Bryers; William M Reichert
Journal:  Biomaterials       Date:  2009-01-29       Impact factor: 12.479

8.  Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.

Authors:  M R Wessels; L C Paoletti; A K Rodewald; F Michon; J DiFabio; H J Jennings; D L Kasper
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

9.  Immunochemistry of capsular type polysaccharide and virulence properties of type VI Streptococcus agalactiae (group B streptococci).

Authors:  C von Hunolstein; S D'Ascenzi; B Wagner; J Jelínková; G Alfarone; S Recchia; M Wagner; G Orefici
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

10.  Complement and antibody participation in opsonophagocytosis of type IV and V group B streptococci.

Authors:  M A Hall; M S Edwards; C J Baker
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.